Teresa Regan
Human Resources Officer bij NEON THERAPEUTICS, INC.
Momenteel actieve connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Richard Gaynor | M | 74 | 8 jaar | |
Frederick B. Oleson | M | - | 27 jaar |
Relatiegrafiek
Connectie in verschillende bedrijven
Oude connecties
Naam | Geslacht | Leeftijd | Verwante bedrijven | Samenwerking |
---|---|---|---|---|
Robert Perez | M | 59 | 12 jaar | |
David McGirr | M | 69 | 12 jaar | |
Ken Bate | M | 73 | 13 jaar | |
Hugh O'Dowd | M | 59 | 4 jaar | |
Eric S. Lander | M | 67 | 7 jaar | |
Robert Tepper | M | 68 | 7 jaar | |
Mary Crosby Stack | F | - | - | |
Cary Pfeffer | M | 61 | 5 jaar | |
Edward S. Campanaro | M | - | - | |
Julian Adams | M | 69 | 1 jaar | |
Christopher Guiffre | M | 56 | 7 jaar | |
Robert Kamen | M | 79 | 5 jaar | |
Stephen Sherwin | M | 75 | 5 jaar | |
Meryl Zausner | F | 67 | 3 jaar | |
Jolie Siegel | F | 48 | 2 jaar | |
Andrea Corcoran | F | 61 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 jaar |
J. Singleton | M | 71 | 11 jaar | |
Yasir Al-Wakeel | M | 42 | 3 jaar | |
Antonin Rollet de Fougerolles | M | 59 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 1 jaar |
Bart Jones | M | - | - | |
Daniella Beckman | F | 45 | 4 jaar | |
Timothy J. Douros | M | - | - | |
Titus M. F. M. Plattel | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 jaar |
Donna M. Jarlenski | F | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 2 jaar |
Gregory Stea | M | 66 | 13 jaar | |
Mary E. Taylor | F | 65 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
Christopher Rovaldi | M | 50 | 4 jaar | |
Barbara Weber | M | 67 | 2 jaar | |
Robert Bazemore | M | 56 | 2 jaar | |
René Russo | M | 49 | 12 jaar | |
Bob Ang | M | 49 | 4 jaar | |
Jeffrey D. Alder | M | - | - | |
Halley Gilbert | F | 54 | 6 jaar | |
Walter R. Maupay | M | 84 | 11 jaar | |
Robert D. Arbeit | M | 76 | 2 jaar | |
Susan B. Bayh | F | 64 | 4 jaar | |
David W. Martin | M | 82 | 12 jaar | |
Francis P. Tally | M | 83 | 9 jaar | |
Thomas A. Shea | M | 64 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 6 jaar |
Dennis D. Keith | M | 80 | - | |
Thomas J. Slater | M | - | - | |
Barry I. Eisenstein | M | 75 | - | |
Praveen Tipirneni | M | 55 | 13 jaar | |
Oliver Fetzer | M | 60 | 5 jaar | |
Elizabeth Czerepak | F | 58 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 4 jaar |
John Finn | M | 68 | 5 jaar | |
David Wood | M | 66 | 3 jaar | |
Robert M. Kirsch | M | - |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | - |
Xiang Liu | M | - | 3 jaar | |
Anthony S. Murabito | M | - | - | |
Maureen H. Powers | F | - | - | |
Aoife Brennan | M | 48 |
Tolerx, Inc.
Tolerx, Inc. BiotechnologyHealth Technology Tolerx, Inc. operates as a biopharmaceutical company in the discovery and development of therapies for immune-mediated diseases. They are also engaged in preclinical development of monoclonal antibody product candidates that engage the body’s immune system and promote and enhance immune responses. The company was founded in 2000 and is based in Cambridge, MA. | 3 jaar |
Statistieken
Land | Connecties | % van het totaal |
---|---|---|
Verenigde Staten | 54 | 100.00% |
Ouderdom van de connecties
Actief
Verleden
Man
Vrouw
Besturend
Uitvoerend
Oorsprong van de connecties
- Beurs
- Insiders
- Teresa Regan
- Persoonlijk netwerk